NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that it has licensed its procalcitonin biomarker assay, BRAHMS PCT, to Siemens Healthineers.
Siemens' Atellica BRAHMS PCT assay received clearance from the US Food and Drug Administration on July 16, which the company announced in August.
Thermo Fisher said this is the sixth licensing agreement for its BRAHMS PCT assay, which provides information on the presence and severity of bacterial infections and helps physicians decide whether to give antibiotics to patients with lower respiratory tract infections, and whether to discontinue antibiotics in patient with such infections and in patients with sepsis.
"With more than 5,000 customers in 130 countries, it is clear that expanding availability of the PCT biomarker benefits patients and communities," said Patrick Durbin, senior vice president and president of specialty diagnostics at Thermo Fisher, in a statement.
The BRAHMS PCT assay was originally developed by Brahms, a German diagnostics company that was acquired by Thermo Fisher in 2009.